Genomic profiling study brings investigators “one step closer” to liquid biopsy in UTUC
“We’re just getting one step closer to being able to find urine tests that we can use to help risk stratify patients, and then help understand the genetic profiles of other tumors, which might help guide management later on,” says Wesley Yip, MD.
In this video, Wesley Yip, MD, discusses the background and findings of the study, “Feasibility and validation of genomic profiling of upper tract urothelial carcinoma from urine cytology specimens,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Yip is a urologic oncology fellow at the Memorial Sloan Kettering Cancer Center in New York, New York.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
